Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, April 30, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
John Newman Maintained (AGIO) at Strong Buy with Increased Target to $65 on, Apr 30th, 2021
John Newman of Canaccord Genuity, Maintained "Agios Pharmaceuticals, Inc." (AGIO) at Strong Buy with Increased Target from $57 to $65 on, Apr 30th, 2021.
John has made no other calls on AGIO in the last 4 months.
There are 2 other peers that have a rating on AGIO. Out of the 2 peers that are also analyzing AGIO, all agree with John's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Anupam Rama of "JP Morgan" Downgraded from Buy to Hold and Held Target at $54 on, Monday, March 1st, 2021
- Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $50 on, Friday, February 26th, 2021
